GlassScriptPhysician profile
Kaitlyn Kamp
NPI 1376900027
$20,078.81
in general payments reported to CMS, 2019-2025
16 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $2,127 · 2023: $3,077 · 2024: $3,181 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,435 · Food and Beverage: $6,337 · Travel and Lodging: $4,472 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,435.00 |
| Food and Beverage | $6,336.94 |
| Travel and Lodging | $4,471.81 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $13,237.20 | 2021-2025 | |
| Harmony Biosciences LLC | $2,844.58 | 2021-2025 | Wakix |
| Inspire Medical Systems, INC. | $2,215.82 | 2022-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $485.66 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $403.15 | 2022-2025 | Sunosi |
| Itamar Medical INC | $177.11 | 2023-2025 | Watchpatone |
| Avadel Cns Pharmaceuticals, LLC | $174.85 | 2024 | Lumryz |
| Azurity Pharmaceuticals, INC. | $107.17 | 2023-2024 | Horizant, Edarbi, Horizant |
| Fisher & Paykel Healthcare INC | $81.50 | 2022-2024 | Fisher & Paykel Healthcare |
| Resmed Corp | $80.24 | 2022 | |
| Vanda Pharmaceuticals INC. | $79.79 | 2021-2022 | |
| Eisai INC. | $61.75 | 2021-2022 | |
| Novo Nordisk INC | $47.16 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $36.50 | 2023 | Belsomra |
| Arbor Pharmaceuticals, INC. | $24.45 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.88 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Kamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.